4419 T3D4365 L-Leucine L-Leucine belongs to the amino acids, peptides, and analogues, a subclass of carboxylic acids and derivatives within the organic compounds. It has the chemical formula C6H13NO2 and an average molecular weight of 131.17 g/mol. This endogenous compound exists as a solid at room temperature. L-Leucine acts as a metabolite in plants, Escherichia coli, and Saccharomyces cerevisiae, and functions biologically as an antioxidant (PMC4632414, PMC9265340). Industrial applications include its use as an anti-static agent, a softener and conditioner, and a flavouring and nutrient. The compound is detected in various tissues, including the bladder, kidney, intestine, placenta, prostate, testes, epidermis, fibroblasts, nerve cells, neuron, platelet, adrenal medulla, adipose tissue, muscle, and skeletal muscle. It interacts with several protein targets, including Leucine--tRNA ligase, mitochondrial (LARS2), tRNA wybutosine-synthesizing protein 4 (LCMT2), Leucine carboxyl methyltransferase 1 (LCMT1), and Leucine--tRNA ligase, cytoplasmic (LARS1), among four other proteins. L-Leucine is found in 32 recorded sources, including electrical and electronic equipment such as antennas, adjustable resistors, electric hearing aids, conductors or conductive bodies characterised by the conductive materials, and auxiliary devices. It is also found in household cleaning and consumer products, including bleaching agents, perfumes within detergents and soaps, cigar cigarettes, other smoking requisites, and non electric simulated smoking devices. Additionally, it is present in food, food processing and cookware, specifically in the preparation of malt, vinegar, wine or sparkling wine, fermentation processes for beer, and food preservation. Regarding health effects, L-Leucine is used as a treatment for hypertension (PMC12146500) and has a therapeutic effect on fatigue (PMC13400281). It is associated with obesity (PMC7463425) and hemolysis (PMC10011573). Blood levels of the compound are decreased in liver cirrhosis (PMC7913291) and elevated in breast cancer (PMC9910008). 61-90-5 6106 C6H13NO2 White powder. 293°C 2.15E+004 mg/L (at 25°C) This group of essential amino acids are identified as the branched-chain amino acids, BCAAs. Because this arrangement of carbon atoms cannot be made by humans, these amino acids are an essential element in the diet. The catabolism of all three compounds initiates in muscle and yields NADH and FADH2 which can be utilized for ATP generation. The catabolism of all three of these amino acids uses the same enzymes in the first two steps. The first step in each case is a transamination using a single BCAA aminotransferase, with a-ketoglutarate as amine acceptor. As a result, three different a-keto acids are produced and are oxidized using a common branched-chain a-keto acid dehydrogenase, yielding the three different CoA derivatives. Subsequently the metabolic pathways diverge, producing many intermediates. The principal product from valine is propionylCoA, the glucogenic precursor of succinyl-CoA. Isoleucine catabolism terminates with production of acetylCoA and propionylCoA; thus isoleucine is both glucogenic and ketogenic. Leucine gives rise to acetylCoA and acetoacetylCoA, and is thus classified as strictly ketogenic. There are a number of genetic diseases associated with faulty catabolism of the BCAAs. The most common defect is in the branched-chain a-keto acid dehydrogenase. Since there is only one dehydrogenase enzyme for all three amino acids, all three a-keto acids accumulate and are excreted in the urine. The disease is known as Maple syrup urine disease because of the characteristic odor of the urine in afflicted individuals. Mental retardation in these cases is extensive. Unfortunately, since these are essential amino acids, they cannot be heavily restricted in the diet; ultimately, the life of afflicted individuals is short and development is abnormal The main neurological problems are due to poor formation of myelin in the CNS. No indication of carcinogenicity to humans (not listed by IARC). Indicated to assist in the prevention of the breakdown of muscle proteins that sometimes occur after trauma or severe stress. 2014-08-29T06:35:14Z 2026-05-14T16:24:17Z L-Leucine C00123 15603 LEU DB00149 LEU true CC(C)C[C@H](N)C(O)=O C6H13NO2 InChI=1S/C6H13NO2/c1-4(2)3-5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/t5-/m0/s1 ROHFNLRQFUQHCH-YFKPBYRVSA-N 131.1729 131.094628665 Endogenous Solid -1.52 HMDB00687 CHEMBL291962 5880 <p>Takayasu Tsuchida, Haruo Momose, Yoshio Hirose, &#8220;Process for producing L-leucine.&#8221; U.S. Patent US3970519, issued February, 1975.</p> CHEM003325 NS00125065 (2S)-2-amino-4-methylpentanoic acid 63.31999999999999 34.1709 14.158501021186428 3 3 2 2.7877088821858544 9.51901425787269 0 0 -1.82 -0.27 6.98e+01 g/l Organic compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues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c00010000442000a0000080110000000000004000002000620100000000004000002200000020000009000c2000000040000000001000503000002000801001046004111800000010000200440008044000000800020088000000100400024440100000040800000000000043000000004000000008000024001042c0020000000800000000100000000000000000044000000080020000400000000000000000400000000000080000000000080000000000004000000000000000000000004000200000000050400002 ï¾­Þ���������������� �������€���`�������`�������`�������`������ 4��������`�������(�������h��������(�������������������������� ��(�B�������������� 2026-09-19T04:01:15Z